Respiratory syncytial virus prophylaxis with palivizumab is not associated with 
improved lung function in infants of very low birth weight at early school age

Fortmann, Ingmar; Dammann, Marie-Theres; Humberg, Alexander; Kraft, Hannah; Herz, Alexander; Hanke, Kathrin; Faust, Kirstin; Ricklefs, Isabell; Zemlin, Michael; Liese, Johannes; Engels, Geraldine; Härtel, Christoph; Fortmann-Grote, Carsten; Kopp, Matthias Volkmar; Brinkmann, Folke; Herting, Egbert; Göpel, Wolfgang; Stichtenoth, Guido

doi:10.1016/j.chpulm.2023.100026

アイテム詳細

登録内容を編集ファイル形式で保存

一時保存へ追加

タグ情報を表示リリース履歴を表示詳細要約

公開

学術論文

Respiratory syncytial virus prophylaxis with palivizumab is not associated with improved lung function in infants of very low birth weight at early school age

MPS-Authors

/persons/resource/persons251025

Fortmann-Grote, Carsten
Department Microbial Population Biology, Max Planck Institute for Evolutionary Biology, Max Planck Society;

External Resource

There are no locators available

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

フルテキスト (公開)

1-s2.0-S2949789223000260-main.pdf
(出版社版), 629KB

付随資料 (公開)

There is no public supplementary material available

引用

Fortmann, I., Dammann, M.-T., Humberg, A., Kraft, H., Herz, A., Hanke, K., Faust, K., Ricklefs, I., Zemlin, M., Liese, J., Engels, G., Härtel, C., Fortmann-Grote, C., Kopp, M. V., Brinkmann, F., Herting, E., Göpel, W., & Stichtenoth, G. (2024). Respiratory syncytial virus prophylaxis with palivizumab is not associated with improved lung function in infants of very low birth weight at early school age. CHEST Pulmonary, 2(1):. doi:10.1016/j.chpulm.2023.100026.

引用: https://hdl.handle.net/21.11116/0000-000E-7AEA-2

要旨

Background
Prematurity and infection with respiratory syncytial virus (RSV) are major risk factors for impaired lung function beyond the neonatal period.

Research Question
What are the long-term effects of palivizumab immunoprophylaxis in the first year of life on lung function and frequency of bronchitis episodes in 5- to 6-year-old preterm infants?

Study Design and Methods
Preterm infants with a birth weight < 1,500 g (very low-birth weight infants [VLBWIs]) were enrolled in a German Neonatal Network cohort study between 2009 and 2016. Children were examined by a single follow-up team at 5 to 6 years of age. VLBWIs who received at least five doses of palivizumab were compared with children who never received palivizumab. Analyses were stratified by bronchopulmonary dysplasia (BPD) and gestational age. We analyzed FVC, FEV1, FEV1 to FVC ratio, and the risk of respiratory tract infections at 5 to 6 years of age via univariate analyses and linear and logistic regression models.

Results
Of 1,986 VLBWIs with follow-up at 5 to 6 years of age, 951 infants (48%) received immunoprophylaxis with palivizumab. Children with BPD (n = 1,019) showed a much lower FEV1 than children without BPD (median FEV1 z score, –1.51 vs –1.09; P < .001). However, FEV1 in children with BPD was not altered by palivizumab (median FEV1 z score in 698 children with BPD who received palivizumab, –1.57 [interquartile range, –0.75 to –2.43] vs in 320 children with BPD who did not receive palivizumab, –1.37 [interquartile range, –0.69 to –2.25]; P = .1). As for FEV1, we did not find any protective effects of palivizumab for other end points or in other risk groups.

Interpretation
Palivizumab immunoprophylaxis in VLBWIs is not associated with improved lung function or lower rates of respiratory tract infections in early school-age infants.